The United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed novel coronavirus (COVID-19) in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). To read the FDA announcement and summary of the issuance of an EUA for baricitinib, in combination with remdesivir, to treat COVID-19, use the link below.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19?utm_medium=email&utm_source=govdelivery